NASDAQ: TLRYTilray Brands Inc Stock
$1.13-0.04 (-3.42%)
Updated Jan 22, 2025
TLRY Price
$1.13
Fair Value Price
N/A
Market Cap
$1.06B
52 Week Low
$1.13
52 Week High
$2.97
P/E
-3.77x
P/B
0.31x
P/S
1.4x
PEG
N/A
Dividend Yield
N/A
Revenue
$829.22M
Earnings
-$248.96M
Gross Margin
30.5%
Operating Margin
-29.06%
Profit Margin
-30%
Debt to Equity
0.21
Operating Cash Flow
-$61M
Beta
1.52
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
TLRY Overview
Tilray Brands, Inc. engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company operates through four segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. It offers medical and adult-use cannabis products, including GMP-certified flowers, oils, vapes, edibles, and topicals; purchases and resells pharmaceutical and wellness products; and produces, markets, sells, and distributes beverage alcohol products, and hemp-based food and other wellness products. The company offers its products under the Tilray, Aphria, Broken Coast, Symbios, B!NGO, The Batch, P'tite Pof, Dubon, Good Supply, Solei, Chowie Wowie, Canaca, RIFF, SweetWater, Breckenridge Distillery, Alpine Beer Company, and Green Flash brands. It sells its products to retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, and governments, as well as direct to consumers. The company was formerly known as Tilray, Inc. Tilray Brands, Inc. is headquartered in Leamington, Canada.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine TLRY's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Value
C
Growth
F
Momentum
F
Sentiment
B
Safety
D
Financials
D
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
TLRY
Ranked#56 of 61
Ranked#56 of 61
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $38.17 | A | |
| $21.76 | A | |
| $14.66 | A |
Be the first to know about important TLRY news, forecast changes, insider trades & much more!
TLRY News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TLRY scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TLRY is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
TLRY is good value based on its book value relative to its share price (0.31x), compared to the US Drug Manufacturers - Specialty & Generic industry average (2.26x)
P/B vs Industry Valuation
TLRY is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more TLRY due diligence checks available for Premium users.
Valuation
TLRY price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.77x
Industry
4.47x
Market
30.67x
TLRY price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.31x
Industry
2.26x
TLRY is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TLRY's financial health
Profit margin
Revenue
$211.0M
Net Income
-$85.3M
Profit Margin
-40.5%
TLRY's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
TLRY's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$4.2B
Liabilities
$738.1M
Debt to equity
0.21
TLRY's short-term assets ($707.34M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TLRY's short-term assets ($707.34M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TLRY's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TLRY's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$40.7M
Investing
-$10.7M
Financing
$38.2M
TLRY's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TLRY vs Pharmaceutical Stocks
Tilray Brands Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.